A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Female
Gene Rearrangement
Genotype
HSP90 Heat-Shock Proteins
Humans
Lung Neoplasms
Male
Middle Aged
Mutation
Neoplasm Staging
Receptor Protein-Tyrosine Kinases
Treatment Outcome
Triazoles

authors with profiles

Ravi Salgia